君实生物(01877.HK)澄清未有安排配发新股或作任何讨论
君实生物医药(01877.HK)公布,关注到有若干媒体报道,指公司将发行950万股H股新股一事。
公司澄清,至今未就发行或配售公司新股份与任何第三方进行商讨、亦无就发行或配售公司股份订立任何协议或安排。
君实生物新冠双抗体疗法三期临床达主要研究终点,但传遭股东趁高配股,今早市前有一宗950万股以每股82.12元(较昨日收市价折让约8.8%)非自动对盘上板,涉资逾7.8亿元。该股扭转连日破顶升势,股价曾急吐20%低见72元,半日收79.05元,急吐12%,一向薄弱成交受配股上板带动急增至1,268万股,涉资10.26亿元;君实A股也跌逾6%曾低见84.48元人民币。(ic-sz/k)~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.